A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml

Exclusion Criteria

• •Neutrophil count \<1.5 x 109cells/L or platelet count \<90 x 109cells/L
• •Co-infections with HIV, HAV, HCV, HDV or HEV
• •Women with ongoing pregnancy or breast feeding, or wishing to become pregnant during the study period
• •Prolonged and excessive alcohol intake (\> 40g/day for men and \> 30g/day for women)
• •Active intravenous drug abuse
• •History or current treatment with telbivudine
• •Treatment with immunomodulators (e.g. Interferon) for less than one year before study enrollment
• •Treatment with immunosuppressors (including systemic corticosteroids) or anti-neoplastic treatment (including radiation therapy) \<=6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study
• •Serum concentrations of ceruloplasmin or alfa-antitrypsin consistent with an increased risk of metabolic disease
• •History or other evidence of chronic pulmonary disease associated with functional limitation
• •History of severe cardiac disease
• •History of the severe seizure disorder or current anticonvulsivant use
• •History of thyroid disease poorly controlled on prescribed medications. Patients with elevated thyroid stimulating hormone concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease
• •History or other evidence of severe retinopathy
• •History of autoimmune disease or presence of a significant level of auto-antibodies
• •Renal insufficiency (creatinine clearance of \< 50 ml/min according to the Cockroft and Gault equation), kidney transplant, hemodialysis
• •History of depression or uncontrolled psychiatric disorders
• •Subjects protected by law or not in a position to give consent
• •Patients with reproductive potential not willing to use an effective method of contraception.
• •Evidence of an active or suspected cancer or a history of malignancy (other than basocellular carcinoma or in-situ cervical carcinoma)